Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 July 2019 | Story Ruan Bruwer | Photo Tania Allen
Tanya von Berg
Tanya von Berg has represented the UFS netball team with distinction over seven years, winning three Varsity Netball titles and one USSA crown.

Although she did not quite reach her final goal in a Kovsie netball dress, being honoured one last time brought much peace to Tanya von Berg.

She was named in the Dream Team at the conclusion of the University Sport South Africa (USSA) tournament in Johannesburg and was thus recognised as the best centre at the competition.

According to the stalwart who played in her seventh year for the University of the Free State, her goal was to make this team and lift the trophy. The team didn’t succeed in the latter, losing to the North-West University in the semi-final.

Heading abroad
“Knowing that it would be the last time I would be playing for the team, I set myself these two goals. Although we were not able to claim the title, at least making the Dream Team helped to make me feel that I finished on a high, giving my all one last time,” she said.

Von Berg, who is doing her honours in Education this year, received a teaching post in Qatar, where she will start in August.

Remarkably this versatile player, who could play any one of four positions, only missed two matches in the two student competitions since making her debut as a first-year student in 2013. This was due to national commitments in 2016 (playing for South Africa A) and her honeymoon last year.

Standout moments
“Being named for the Protea training squad in 2016 and being selected for the national Fast5 team later that year, was the two outstanding moments of my career.”
“What I remember about my first year, was how huge it was to play with the seniors. The one player who served as my biggest inspiration, was Isélma Parkin. She didn’t receive the recognition she deserved. I learned from her to continue to work hard and to never give up.”


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept